Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New acid blocker may beat standard treatment for stomach bug

NCT ID NCT07537634

Disease control Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer acid-reducing drug (vonoprazan) works better than a standard one (esomeprazole) for clearing H. pylori, a bacteria that can cause stomach ulcers and indigestion. About 80 adults with H. pylori will take one of the two drug combinations for 14 days. Four weeks later, a stool test will check if the infection is gone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan or esomeprazole, each combined with amoxicillin and levofloxacin
What this could lead to
If vonoprazan works better, it could offer a more effective option for clearing H. pylori infections, reducing the risk of ulcers and stomach issues.
What could go wrong
This is a small, early-phase 4 trial with only 80 participants, so results may not apply to everyone. Both regimens include antibiotics, which can cause side effects like diarrhea or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Dyspeptic patients with positive for both rapid urease test and stool antigen test 3. Patients giving written informed consent Exclusion Criteria: 1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study 2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study 3. Previous H. pylori eradication therapy 4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy 5. Significant upper or lower gastrointestinal bleeding within 4 weeks 6. Patients with regular intake of NSAIDs or steroids 7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy 8. Known case of malignancy, including MALToma 9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease) 10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months 11. Pregnant, lactating woman or intend to become pregnant within the study period 12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and/or levofloxacin 13. On colchicine 14. Subjects with abnormal laboratory test at the start of the screening period: S. creatinine \> 2 mg/dl SGPT \> 2 x Upper limit of normal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyspepsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dyspepsia Helicobacter pylori infectious disease peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyspepsia H pylori Helicobacter pylori Helicobacter pylori infection Peptic ulcer disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bangabandhu Sheikh Mujib Medical University

    NOT_YET_RECRUITING

    Dhaka, Bangladesh

  • Bangabandhu Sheikh Mujib Medical University

    RECRUITING

    Dhaka, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.